$6.11
1.75%
Nasdaq, Apr 21, 08:17 pm CET
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Novavax, Inc. Stock price

$6.00
-2.38 28.40% 1M
-4.35 42.03% 6M
-2.04 25.37% YTD
+2.11 54.24% 1Y
-49.16 89.12% 3Y
-13.08 68.55% 5Y
-155.40 96.28% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.20 3.23%
ISIN
US6700021040
Symbol
NVAX
Sector
Industry

Key metrics

Market capitalization $965.06m
Enterprise Value $294.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.43
P/S ratio (TTM) P/S ratio 1.41
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -30.65%
Revenue (TTM) Revenue $682.16m
EBIT (operating result TTM) EBIT $-231.94m
Free Cash Flow (TTM) Free Cash Flow $-100.32m
Cash position $933.74m
EPS (TTM) EPS $-1.32
P/E forward 11.73
P/S forward 1.47
EV/Sales forward 0.45
Short interest 28.57%
Show more

Is Novavax, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Novavax, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Novavax, Inc. forecast:

4x Buy
57%
2x Hold
29%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Novavax, Inc. forecast:

Buy
57%
Hold
29%
Sell
14%

Financial data from Novavax, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
682 682
31% 31%
100%
- Direct Costs 196 196
40% 40%
29%
486 486
26% 26%
71%
- Selling and Administrative Expenses 283 283
35% 35%
41%
- Research and Development Expense 387 387
47% 47%
57%
-183 -183
64% 64%
-27%
- Depreciation and Amortization 49 49
18% 18%
7%
EBIT (Operating Income) EBIT -232 -232
58% 58%
-34%
Net Profit -188 -188
66% 66%
-27%

In millions USD.

Don't miss a Thing! We will send you all news about Novavax, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novavax, Inc. Stock News

Neutral
PRNewsWire
6 days ago
Preliminary data showed Novavax's non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side effects and impact on daily life compared with Pfizer-BioNTech mRNA vaccine Full results will be submitted for publication later this year GAITHERSBURG, Md. , April 15, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced preliminary results from the SHIELD-Utah ...
Negative
Reuters
11 days ago
Vaccine maker Novavax's shares plunged over 22% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about the company's COVID-19 vaccine in an interview with CBS News.
Positive
The Motley Fool
13 days ago
President Trump's trade policies are sending many stocks that were performing well in the wrong direction and exacerbating things for others that were already struggling. So, the time seems ripe for investors to look for bargains.
More Novavax, Inc. News

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Head office United States
CEO John Jacobs
Employees 952
Founded 1987
Website www.novavax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today